Browse by category

Metabolic bariatric surgery (MBS) may improve psoriasis severity, quality of life and treatment requirements - weight loss magnitude, type of MBS and patient characteristics might affect clinical response of psoriasis, however, the current evidence is uncertain, according to researchers from Hull University Teaching Hospitals NHS Trust, in the UK. (Credit: Bobjgalindo) The researchers noted that although MBS has been associated with improved clinical outcomes of psoriasis, ye

The postoperative complications of medical tourism may be costing the NHS up to £20,000 per patient, suggest the findings of a rapid review of the available data performed by UK researchers. However, data on the use, frequency and consequences for the NHS are incomplete and haphazard, making it currently impossible to fully understand the risks of opting for surgery overseas, the researchers warned. "There are areas of the UK, such as Wales and the South West of England, whic

Kailera Therapeutics has announced the randomisation of the first participants in the KaiNETIC global Phase 3 clinical program of ribupatide (also known as KAI-9531), an investigational once-weekly injectable dual GLP-1/GIP receptor agonist peptide, for the treatment of people living with obesity or overweight. The KaiNETIC global Phase 3 clinical program includes three global, double-blind, randomized, placebo-controlled Phase 3 trials (KaiNETIC-1, KaiNETIC-2, and KaiNETIC-3

Outcomes from Viking Therapeutics’ Phase 2 VENTURE clinical trial of VK2735 - a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors – reveal that after 13 weekly subcutaneous doses, participants receiving VK2735 demonstrated statistically significant reductions in mean body weight from baseline, ranging up to 14.7% with no signs of plateau. The outcomes highlights the previously reported positive results from th

Both the new weight loss drugs and bariatric surgery improve body composition in patients with obesity by inducing a moderate loss of fat-free mass (including lean muscle) along with a substantial reduction in fat, researchers at Vanderbilt Health have found. Weight loss study team: From left, Danxia Yu, PhD, Zicheng Wang, MS, Lei Wang, PhD, and Jason Samuels, MD, are co-authors of a paper evaluating body composition changes after bariatric surgery or treatment with the new w

A study led by Assistant Professor Anne Loft, Associate Professor Jesper Grud Skat Madsen and Professor Susanne Mandrup from University of Southern Denmark sheds light on what happens in the fat tissue during weight loss. All three are leading researchers at the Center of Excellence ATLAS, which investigates the molecular mechanisms driving changes in liver and fat tissues in response to obesity and weight loss. This knowledge is important because obesity-induced dysfunction

Rani Therapeutics has initiated a Phase 1 clinical trial to evaluate the safety, tolerability, bioavailability and pharmacokinetics and pharmacodynamics of single and multiple doses of RT-114, an orally administered RaniPill capsule containing a GLP-1/GLP-2 dual agonist, PG-102, for the treatment of obesity. RaniPill PG-102 is a fc-fusion protein conjugated GLP-1/GLP-2 dual agonist in development by ProGen, which recently announced preclinical and clinical data, at the 2025 E

Stopping weight loss drugs is followed by weight regain and reversal of beneficial effects on heart and metabolic health markers such as high cholesterol and high blood pressure, according to a study by University of Oxford researchers. The study shows that the average rate of weight regain is 0.4kg/month after stopping treatment, with weight and risk markers for diabetes and heart disease predicted to return to pre-treatment levels in less than two years. It also finds that

Researchers at Leipzig University and the University of Gothenburg have developed a novel approach to assessing an individual's risk of metabolic diseases such as diabetes or fatty liver disease more precisely. Instead of relying solely on the widely used body mass index (BMI), the team developed an AI-based computational model using metabolic measurements. Systems view of metabolic obesity: integrating multi-organ and multi-omics signatures. Credit: Nature Medicine (2026). D

People prescribed the new generation of weight loss drugs may not receive sufficient nutritional guidance to support safe and sustainable weight loss, leaving them vulnerable to nutritional deficiencies and muscle loss, according to University College London (UCL) and University of Cambridge researchers. The research led by Dr Marie Spreckley from the University of Cambridge, found a lack of robust evidence surrounding nutritional advice and support and the impact this has on